- ?? Blog ActionCovid1984.org
- ?? Irish Examiner
- Inverse
- ?? Gript media
- Blake-Lemoine - LaMBDA
- ?? Over Dee Wall
- The Defender News
- ?? BreakingNews.ie
- Dr Vernon Coleman
- Rebel News
- Vaccine Choice Canada NEWS
- SHFT Plan
- The Expose
- ?? Robert Pierzyński PJ
- James Roguskii - Substack
- ?? The Burkean
- Liberty Tactics IM
- stewpeters.com
- Technocracy News
- Interesting Engineering
- ?? Media Hub Ireland
- ?? The Irish Inquiry
- ?? Andy Heasman
- ?? GriptMedia
- ?? WeThePeople.ie
- ?? Action-Covid-1984
- ?? Lets wake up our Capital
- ?? Lets Wake Up Call!!!
- WW Freedom Rallies
- Piers Corbyn
- ?? Tracey OMahony
- ?? The Irish Git
- eIRe is falling
- Peter Madden Channel
- rish Farmers,Food & Family
- Gemma O'Doherty
What's new
What's new
International Coalition of Medicines Regulatory Authorities (ICMRA)
International Coalition of Medicines Regulatory Authorities (ICMRA)
21 November 2024
Human medicines European public assessment report (EPAR): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), Date of authorisation: 17/12/2020, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Palforzia, defatted powder of Arachis hypogaea L., semen (peanuts), Date of authorisation: 17/12/2020, Revision: 7, Status: Authorised
21 November 2024
Veterinary medicines European public assessment report (EPAR): Fevaxyn Pentofel, inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis, Status: Withdrawn (authorisation)
Veterinary medicines European public assessment report (EPAR): Fevaxyn Pentofel, inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis, Status: Withdrawn (authorisation)
21 November 2024
Human medicines European public assessment report (EPAR): Tenkasi (previously Orbactiv), oritavancin, Date of authorisation: 19/03/2015, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Tenkasi (previously Orbactiv), oritavancin, Date of authorisation: 19/03/2015, Revision: 16, Status: Authorised
20 November 2024
Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 20, Status: Authorised
Human medicines European public assessment report (EPAR): Mycamine, micafungin, Date of authorisation: 25/04/2008, Revision: 20, Status: Authorised
20 November 2024
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0451/2023
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0451/2023
20 November 2024
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0446/2023
Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, upadacitinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0446/2023
20 November 2024